Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.24 billion. The enterprise value is $726.49 million.
Important Dates
The next estimated earnings date is Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 162.50 million shares outstanding. The number of shares has increased by 16.16% in one year.
| Current Share Class | 162.50M |
| Shares Outstanding | 162.50M |
| Shares Change (YoY) | +16.16% |
| Shares Change (QoQ) | -8.39% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 52.14% |
| Float | 134.88M |
Valuation Ratios
The trailing PE ratio is 3.68.
| PE Ratio | 3.68 |
| Forward PE | n/a |
| PS Ratio | 1.16 |
| Forward PS | 3.52 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 2.13 |
| EV / Sales | 0.68 |
| EV / EBITDA | 1.61 |
| EV / EBIT | 1.74 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.27
| Current Ratio | 2.27 |
| Quick Ratio | 1.85 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.56 |
| Debt / FCF | n/a |
| Interest Coverage | 13.84 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 18.01% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 55.57% |
| Revenue Per Employee | $1.12M |
| Profits Per Employee | $358,976 |
| Employee Count | 952 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 39.01 |
Taxes
In the past 12 months, Novavax has paid $8.94 million in taxes.
| Income Tax | 8.94M |
| Effective Tax Rate | 2.55% |
Stock Price Statistics
The stock price has decreased by -21.93% in the last 52 weeks. The beta is 2.37, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 2.37 |
| 52-Week Price Change | -21.93% |
| 50-Day Moving Average | 7.07 |
| 200-Day Moving Average | 7.32 |
| Relative Strength Index (RSI) | 67.87 |
| Average Volume (20 Days) | 3,376,335 |
Short Selling Information
The latest short interest is 52.59 million, so 32.36% of the outstanding shares have been sold short.
| Short Interest | 52.59M |
| Short Previous Month | 51.86M |
| Short % of Shares Out | 32.36% |
| Short % of Float | 38.99% |
| Short Ratio (days to cover) | 15.17 |
Income Statement
In the last 12 months, Novavax had revenue of $1.06 billion and earned $341.75 million in profits. Earnings per share was $2.07.
| Revenue | 1.06B |
| Gross Profit | 632.62M |
| Operating Income | 416.82M |
| Pretax Income | 350.68M |
| Net Income | 341.75M |
| EBITDA | 451.83M |
| EBIT | 416.82M |
| Earnings Per Share (EPS) | $2.07 |
Full Income StatementBalance Sheet
The company has $762.89 million in cash and $251.14 million in debt, with a net cash position of $511.75 million or $3.15 per share.
| Cash & Cash Equivalents | 762.89M |
| Total Debt | 251.14M |
| Net Cash | 511.75M |
| Net Cash Per Share | $3.15 |
| Equity (Book Value) | -156.67M |
| Book Value Per Share | -0.96 |
| Working Capital | 544.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$378.32 million and capital expenditures -$5.42 million, giving a free cash flow of -$383.74 million.
| Operating Cash Flow | -378.32M |
| Capital Expenditures | -5.42M |
| Free Cash Flow | -383.74M |
| FCF Per Share | -$2.36 |
Full Cash Flow StatementMargins
Gross margin is 59.42%, with operating and profit margins of 39.15% and 32.10%.
| Gross Margin | 59.42% |
| Operating Margin | 39.15% |
| Pretax Margin | 32.94% |
| Profit Margin | 32.10% |
| EBITDA Margin | 42.44% |
| EBIT Margin | 39.15% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.16% |
| Shareholder Yield | -16.16% |
| Earnings Yield | 27.60% |
| FCF Yield | -30.99% |
Analyst Forecast
The average price target for Novavax is $9.75, which is 27.95% higher than the current price. The consensus rating is "Hold".
| Price Target | $9.75 |
| Price Target Difference | 27.95% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | -8.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Novavax has an Altman Z-Score of -2.23 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.23 |
| Piotroski F-Score | 5 |
